ArticleCancers2022

Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide.

Keith M Skubitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.